The Science Behind MAMOSURE

Understanding the Science Behind MAMOSURE

Research Partners

ACTREC-Tata Memorial Centre
India's premier cancer research institution, where our formulation underwent rigorous clinical testing.

Haffkine Institute for Training, Research and Testing (HITRT)
Prestigious government research facility that validated our safety and efficacy protocols.

Clinical Study Results

MCF7 Breast Cancer Cell Line Study
Objective: Evaluate cytotoxic effects on hormone-receptor positive breast cancer cells
Results: Significant cytotoxicity with proven G0/G1 and G2 cell-cycle arrest
Significance: Demonstrates effectiveness against most common breast cancer type

MDA-MB-231 Triple Negative Study
Objective: Test efficacy against aggressive triple-negative breast cancer                Results: Successful apoptosis induction and G0/G1 cell-cycle arrest
Significance: Effective against most difficult-to-treat breast cancer subtype

 Safety & Toxicity Profile
In-Vivo Testing: Comprehensive safety evaluation in living systems
Results: Complete non-toxicity to normal, healthy cells confirmed
Clinical Significance: Safe for long-term preventive use

Mechanism of Action

1. DNA Cell-Cycle Regulation
Our active compounds interfere with abnormal DNA replication patterns, preventing malignant cell proliferation.

2. Selective Apoptosis Induction
The formulation triggers programmed cell death specifically in cancer cells while preserving healthy tissue.

3. Cellular Environment Optimization
Creates an unfavorable environment for cancer cell growth and metastasis.

Awards & Recognition

2019: National IP Award for Innovation in Healthcare
2020: Industry Excellence Award for Breakthrough Research  
2021: Innovation Award for Cancer Prevention Technology
2022: National Recognition for Healthcare Impact